Serrapeptase

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Serrapeptase
Accession Number
DB13131
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular infections. Serratiopeptidase is under investigation in clinical trial NCT02493179 (Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery).

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Serratiopeptidase
Categories
UNII
NL053ABE4J
CAS number
95077-02-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Serrapeptase.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with 5-androstenedione.Experimental, Illicit
AbciximabSerrapeptase may increase the anticoagulant activities of Abciximab.Approved
AcebutololSerrapeptase may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolSerrapeptase may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Serrapeptase.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Alendronic acid.Approved
AliskirenSerrapeptase may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Alminoprofen.Experimental
AlprenololSerrapeptase may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Serrapeptase.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Amcinonide.Approved
AmikacinSerrapeptase may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideSerrapeptase may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Aminosalicylic Acid.Approved
AmiodaroneSerrapeptase may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AncrodSerrapeptase may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Serrapeptase.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Serrapeptase.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Antipyrine.Approved, Investigational
Antithrombin III humanSerrapeptase may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Antrafenine.Approved
ApixabanSerrapeptase may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Serrapeptase.Investigational
ApramycinSerrapeptase may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Serrapeptase.Approved, Investigational
ArbekacinSerrapeptase may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinSerrapeptase may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanSerrapeptase may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololSerrapeptase may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineSerrapeptase may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Atamestane.Investigational
AtenololSerrapeptase may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Serrapeptase.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Serrapeptase.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Serrapeptase.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Serrapeptase.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Balsalazide.Approved, Investigational
BecaplerminSerrapeptase may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSerrapeptase may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinSerrapeptase may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Serrapeptase.Approved
BenorilateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Serrapeptase.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Serrapeptase.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Serrapeptase.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Betamethasone.Approved, Vet Approved
BetaxololSerrapeptase may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Serrapeptase.Approved, Investigational
BevantololSerrapeptase may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Serrapeptase.Approved, Investigational
BisoprololSerrapeptase may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSerrapeptase may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSerrapeptase may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Serrapeptase.Investigational
BucindololSerrapeptase may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Bufexamac.Approved, Experimental
BufuralolSerrapeptase may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Serrapeptase.Approved
BupranololSerrapeptase may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Serrapeptase.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Serrapeptase.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Serrapeptase.Approved
CarprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololSerrapeptase may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSerrapeptase may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Serrapeptase.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Celecoxib.Approved, Investigational
CeliprololSerrapeptase may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinSerrapeptase may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Serrapeptase.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Serrapeptase.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Serrapeptase.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Serrapeptase resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Cimicoxib.Investigational
CinoxacinSerrapeptase may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinSerrapeptase may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Cisplatin.Approved
Citric AcidSerrapeptase may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Serrapeptase.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Serrapeptase.Vet Approved
CloranololSerrapeptase may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Serrapeptase resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Serrapeptase resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Serrapeptase.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Serrapeptase.Experimental
CyclosporineSerrapeptase may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateSerrapeptase may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinSerrapeptase may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSerrapeptase may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSerrapeptase may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Delapril.Experimental
DesipramineSerrapeptase may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinSerrapeptase may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Serrapeptase.Approved, Investigational
DextranSerrapeptase may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinSerrapeptase may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Serrapeptase.Approved, Vet Approved
DicoumarolSerrapeptase may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Serrapeptase.Approved
DihydrostreptomycinSerrapeptase may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Serrapeptase.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Serrapeptase.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Serrapeptase.Approved
DrospirenoneSerrapeptase may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Serrapeptase.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Serrapeptase.Investigational
Edetic AcidSerrapeptase may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSerrapeptase may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Enalaprilat.Approved
EnoxacinSerrapeptase may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinSerrapeptase may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Serrapeptase.Experimental
EpanololSerrapeptase may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Serrapeptase.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Serrapeptase.Experimental
EplerenoneSerrapeptase may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Serrapeptase.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Serrapeptase.Approved
EquileninThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Equilin.Approved
EsatenololSerrapeptase may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololSerrapeptase may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Serrapeptase.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Ethenzamide.Experimental
Ethyl biscoumacetateSerrapeptase may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Serrapeptase.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Serrapeptase.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Serrapeptase.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Serrapeptase.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Serrapeptase.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Serrapeptase.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Feprazone.Experimental
Ferulic acidSerrapeptase may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Serrapeptase.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fish oil.Approved, Nutraceutical
FleroxacinSerrapeptase may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Serrapeptase.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fludrocortisone.Approved, Investigational
FluindioneSerrapeptase may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineSerrapeptase may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Serrapeptase.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Serrapeptase.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Serrapeptase.Approved, Nutraceutical, Vet Approved
FondaparinuxSerrapeptase may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumSerrapeptase may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Serrapeptase.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fosinopril.Approved
FramycetinSerrapeptase may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Serrapeptase.Approved, Vet Approved
GabexateSerrapeptase may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSerrapeptase may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSerrapeptase may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Serrapeptase.Approved, Withdrawn
GemifloxacinSerrapeptase may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSerrapeptase may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSerrapeptase may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASerrapeptase may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinSerrapeptase may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Serrapeptase is combined with HE3286.Investigational
HeparinSerrapeptase may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Serrapeptase.Investigational
HydralazineSerrapeptase may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Serrapeptase.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Serrapeptase.Approved, Investigational
Hygromycin BSerrapeptase may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Serrapeptase.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Serrapeptase.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Icosapent.Approved, Nutraceutical
IdraparinuxSerrapeptase may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Serrapeptase.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Serrapeptase.Approved
IndenololSerrapeptase may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Serrapeptase.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Serrapeptase.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Serrapeptase.Approved, Investigational
IsepamicinSerrapeptase may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Serrapeptase.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Istaroxime.Investigational
KanamycinSerrapeptase may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Serrapeptase.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Serrapeptase.Approved
LabetalolSerrapeptase may decrease the antihypertensive activities of Labetalol.Approved
LandiololSerrapeptase may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Serrapeptase.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Serrapeptase.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Serrapeptase.Approved, Investigational
LepirudinSerrapeptase may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanSerrapeptase may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololSerrapeptase may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololSerrapeptase may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSerrapeptase may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Serrapeptase.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Serrapeptase.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Serrapeptase.Approved
LomefloxacinSerrapeptase may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Serrapeptase.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Serrapeptase.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Serrapeptase.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Serrapeptase.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Serrapeptase.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Serrapeptase is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Mefenamic acid.Approved
MelagatranSerrapeptase may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Meloxicam.Approved, Vet Approved
MepindololSerrapeptase may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Serrapeptase.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Serrapeptase.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Serrapeptase.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Methylprednisolone.Approved, Vet Approved
MetipranololSerrapeptase may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Serrapeptase.Approved
MetoprololSerrapeptase may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinSerrapeptase may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Serrapeptase.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Serrapeptase.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Serrapeptase.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Serrapeptase.Approved
MoxifloxacinSerrapeptase may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Serrapeptase.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Serrapeptase.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Nabumetone.Approved
NadololSerrapeptase may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSerrapeptase may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatSerrapeptase may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Serrapeptase.Approved
Nalidixic AcidSerrapeptase may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Serrapeptase is combined with NCX 1022.Investigational
NeamineSerrapeptase may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololSerrapeptase may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinSerrapeptase may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSerrapeptase may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Nepafenac.Approved, Investigational
NetilmicinSerrapeptase may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Serrapeptase.Investigational
NorfloxacinSerrapeptase may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinSerrapeptase may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Serrapeptase.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Serrapeptase.Approved
OlsalazineSerrapeptase may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Serrapeptase is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Serrapeptase.Vet Approved
OtamixabanSerrapeptase may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Oxaprozin.Approved
Oxolinic acidSerrapeptase may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololSerrapeptase may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Serrapeptase.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Parecoxib.Approved
ParomomycinSerrapeptase may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Serrapeptase.Approved, Investigational
PazufloxacinSerrapeptase may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSerrapeptase may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSerrapeptase may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateSerrapeptase may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateSerrapeptase may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Perindopril.Approved
PhenindioneSerrapeptase may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonSerrapeptase may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Serrapeptase.Approved, Investigational
PindololSerrapeptase may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidSerrapeptase may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Serrapeptase.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Serrapeptase.Approved, Investigational
Piromidic acidSerrapeptase may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorSerrapeptase may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinSerrapeptase may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Serrapeptase.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pomalidomide.Approved
Potassium CitrateSerrapeptase may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololSerrapeptase may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Serrapeptase.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Serrapeptase can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Serrapeptase.Approved, Investigational
PropafenoneSerrapeptase may decrease the antihypertensive activities of Propafenone.Approved
PropranololSerrapeptase may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Serrapeptase.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Serrapeptase.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Serrapeptase.Vet Approved
Protein CSerrapeptase may increase the anticoagulant activities of Protein C.Approved
Protein S humanSerrapeptase may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSerrapeptase may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSerrapeptase may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Serrapeptase.Investigational
PuromycinSerrapeptase may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Serrapeptase.Approved
RamiprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinSerrapeptase may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinSerrapeptase may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Risedronate.Approved, Investigational
RivaroxabanSerrapeptase may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinSerrapeptase may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinSerrapeptase may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Serrapeptase.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Serrapeptase.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Serrapeptase.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Serrapeptase.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Serrapeptase.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Serrapeptase.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Serrapeptase.Approved
SisomicinSerrapeptase may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinSerrapeptase may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateSerrapeptase may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Serrapeptase.Approved
SotalolSerrapeptase may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinSerrapeptase may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Spirapril.Approved
SpironolactoneSerrapeptase may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Serrapeptase.Investigational
StreptomycinSerrapeptase may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Sulindac.Approved, Investigational
SulodexideSerrapeptase may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Serrapeptase.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Suxibuzone.Experimental
TacrolimusSerrapeptase may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Serrapeptase.Approved
TalinololSerrapeptase may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Serrapeptase.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Serrapeptase.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Serrapeptase.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Serrapeptase.Approved, Investigational
TemafloxacinSerrapeptase may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Serrapeptase.Vet Approved
TerbutalineSerrapeptase may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Serrapeptase.Approved
TertatololSerrapeptase may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololSerrapeptase may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Serrapeptase.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Tixocortol.Approved, Withdrawn
TobramycinSerrapeptase may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Serrapeptase.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Serrapeptase.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Serrapeptase.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Serrapeptase.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Serrapeptase.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSerrapeptase may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Serrapeptase.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Serrapeptase.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Trolamine salicylate.Approved
TrovafloxacinSerrapeptase may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinSerrapeptase may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Serrapeptase.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Serrapeptase.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Serrapeptase.Approved
WarfarinSerrapeptase may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSerrapeptase may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Serrapeptase.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Serrapeptase.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Serrapeptase.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911427
Wikipedia
Serrapeptase

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentInflammatory Reaction / Swelling / Trismus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 21:33 / Updated on June 02, 2018 08:46